Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- Versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice

Journal of the International Association of Physicians in AIDS Care

Volumn 9, Issue 6, 2010, Pages 382-389

  Antoniou, Tony ^a,b,c   Raboud, J M ^a,d   Diong, C ^d   Su, D ^d   Dewhurst, N ^a,c   Buckley, V ^b   Kovacs, C ^a,b   Rachlis, A ^a,e   Brunetta, J ^a,b   Smith, G ^a,b   Gough, K ^a,c   Fletcher, D ^a,b   Loutfy, M R ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MAPLE LEAF MEDICAL CLINIC   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

anti HIV drugs; highly active antiretroviral therapy; HIV protease inhibitors; retrospective studies

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; DARUNAVIR; ENFUVIRTIDE; ETRAVIRINE; RALTEGRAVIR; RITONAVIR; TIPRANAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD LEVEL; CD4+ T LYMPHOCYTE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MULTIPLE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ONTARIO; PYRIDINES; PYRONES; RETROSPECTIVE STUDIES; RITONAVIR; SULFONAMIDES; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 78650824233     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109710382041     Document Type: Article

References (16)

1. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 ; 338 (13). 853-860.
2. Hogg RS, Yip B., Kully C., Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 1999 ; 160 (5). 659-665.
3. Harris M., Montaner JS Management of HIV-infected patients with multidrug-resistant virus. Curr HIV/AIDS Rep. 2004 ; 1 (3). 116-121.
4. Boccara F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS. 2008 ; 22 (suppl 3). S19 - S26.
5. Robertson SM, Penzak SR, Pau A. Drug interactions in the management of HIV infection: an update. Expert Opin Pharmacother. 2007 ; 8 (17). 2947-2963.
6. Poppe SM, Slade DE, Chong KT, et al. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother. 1997 ; 41 (5). 1058-1063.
7. De Meyer S., Azijn H., Surleraux D., et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005 ; 49 (6). 2314-2321.
8. Hicks CB, Cahn P., Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006 ; 368 (9534). 466-475.
9. Clotet B., Bellos N., Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007 ; 369 (9568). 1169-1178.
10. AIDS Clinical Trials Group. Table of grading severity of adult adverse experiences. Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD. 2004.
11. Hall DB, Scherer J., Schapiro J., et al. Genotypic relationships between tipranavir and darunavir resistance in protease-inhibitor-experienced patients. Antivir Ther. 2007 ; 12 (suppl 1). S88.
12. Markowitz M., Nguyen BY, Gotuzzo E., et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007 ; 46 (2). 125-133.
13. Saberi P., Caswell NH, Gruta CI, Tokumoto JN, Dong BJ Immunologic benefits of enfuvirtide in patients enrolled in a drug assistance program. Ann Pharmacother. 2008 ; 42 (5). 621-626.
14. Viard JP, Fagard C., Chaix ML, et al. Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients. AIDS. 2009 ; 23 (11). 1383-1388.
15. Svicher V., Aquaro S., D'Arrigo R., et al. Specific enfuvirtide- associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. J Infect Dis. 2008 ; 197 (10). 1408-1418.
16. Hill A., Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med. 2007 ; 8 (8). 259-264.